Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.

Georg Martin Haag,Niels Halama,Christoph Springfeld,Barbara Grün,Leonidas Apostolidis,Stefanie Zschaebitz,Mareike Dietrich,Anne Katrin Berger,Tim F. Weber,Inka Zoernig,Lisa Waberer,Daniel Wilhelm Mueller,Salah-Eddin Al-Batran,Dirk Jaeger

Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.

2020

Georg Martin Haag
Niels Halama
Christoph Springfeld
Barbara Grün
Leonidas Apostolidis
Stefanie Zschaebitz
Mareike Dietrich
Anne Katrin Berger
Tim F. Weber
Inka Zoernig
Lisa Waberer
Daniel Wilhelm Mueller
Salah-Eddin Al-Batran
Dirk Jaeger

3010Background: Checkpoint inhibition using PD-1/PD-L1 inhibitors does not show clinically relevant activity in MSS/pMMR (Mismatch Repair Proficient) colorectal cancer. Previous work showed that in...

Keywords:

Colorectal cancer
Microsatellite Stable
Oncology
Maraviroc
Pembrolizumab
Refractory
Pathology
Internal medicine
Medicine
DNA mismatch repair
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations